A Multicentre Evaluation of the Medtronic AVE Flexible Iliac Bridge Stent in the Iliac Arteries (the First Study)

Abstract

The Medtronic AVE iliac stent has good 30 day and 6 months outcomes supporting the effective use of this device in occlusive disease.

Express LD Vascular Stent in the Treatment of Iliac Artery Lesions: 24-Month Results From the MELODIE Trial

“…The Wallstent and Jostent SelfX demonstrated technical success rates of 99% 25 and 94%, 21 respectively. In this same set of trials, mortality rates at 30 days following the procedure were 2.1%, 20 2.0%, 6 0.8%, 7 2.6%, 23 3.1%, 24 0%, 25 and 0%, 21 respectively. The Express LD stent, with a procedural success rate of 97.1% and a 30-day mortality rate of 0.0%, showed comparable results.…”

“…The 6-month and 1-year primary patency rates of 95.2% and 89.8% reported in the MELODIE trial were similar to the rates seen in other studies, although patency definitions varied across trials. Primary patency in the Zilver, SMART, Wallstent, Perflex, Jostent SelfX, Carnevale Iliac Occlusion Study, Symphony, and AVE Bridge trials were 92.9% at 9 months, 20 94.7% at 1 year, 6 91.1% at 1 year, 6 89% at 1 year, 7 96% at 1 year, 21 87% at 2 years, 26 97.0% at 6 months, 24 and 82.7% at 6 months, 23 respectively. In the MELODIE trial, primary patency at 2 years was 87.8%, demonstrating the durability of the results.…”

“…While it is difficult to directly compare results across trials due to potential differences in patient populations, study design, and study execution, outcomes in MELODIE are similar to those seen in other iliac stenting trials. 6,7,20–23 Like MELODIE, other trials have shown high rates of technical and procedural success and low rates of periprocedural mortality. For example, procedural success rates for the Zilver, SMART, Perflex, Symphony, and AVE Bridge stents were 98.0%, 20 98.2%, 6 94%, 7 95%, 24 and 100%, 23 respectively.…”

“…6,7,20–23 Like MELODIE, other trials have shown high rates of technical and procedural success and low rates of periprocedural mortality. For example, procedural success rates for the Zilver, SMART, Perflex, Symphony, and AVE Bridge stents were 98.0%, 20 98.2%, 6 94%, 7 95%, 24 and 100%, 23 respectively. The Wallstent and Jostent SelfX demonstrated technical success rates of 99% 25 and 94%, 21 respectively.…”

“…Patients in the MELODIE trial also demonstrated clinical and hemodynamic improvements comparable to those seen in other trials. The mean ABI improvement at 6 or 12 months ranged from 0.19 to 0.37 in the Zilver, 20 SMART, 6 Wallstent, 6 Perflex, 7 Jostent SelfX, 21 Symphony, 24 and AVE Bridge 23 stent trials. Similarly, patients treated with the Express LD Vascular stent showed ABI improvement from a baseline value of 0.63 to 0.85 at 2 years.…”